Patent listing

12
Jun
Patent Listings by NDA Sponsors: The Who, What, Why, Where, and How Q&A Document

Patent Listings by NDA Sponsors: The Who, What, Why, Where, and How Q&A Document

Today, the FDA published a draft guidance titled Forms FDA 3542a and FDA 3542: Questions and Answers (here) that provides NDA sponsors with more information on patent submission than perhaps you ever even thought possible.  The document identifies twenty-nine different questions and corresponding answers to clarify who needs to submit patent information, what patent information […]

Read More
30
Aug
Something Wicked This Way Comes - Lachman Blog

Something Wicked This Way Comes?

For those of us that live in areas with seasonal changes, I’m sure everyone has experienced the telltale signs that autumn is right around the corner. These changes are subtle at first but soon gain significance and portend a future that looks different than the present. Individuals who carefully examine the FDA’s Paragraph IV (PIV) Patent […]

Read More
02
Sep
Bumpy Road

Is the Orange Book Patent Listing Process becoming “Divisive”?

The Drug Price Competition and Patent Term Restoration Act of 1984 (better know as Hatch-Waxman) provided a balance between innovation and competition by permitting generic drugs to rely on the safety and efficacy of a previously approved reference listed drug (RLD) rather than unnecessarily repeating duplicative clinical testing to prove what was already known about […]

Read More